Biosynexus Incorporated is a biopharmaceutical company that is developing a monoclonal antibody, pagibaximab, to prevent staphylococcal sepsis in very low birth weight (VLBW) infants in the setting of the neonatal intensive care unit (NICU). The company has two additional product candidates: lysostaphin for the treatment of life threatening staphylococcal infections and nisin a topical cream for treating serious skin infections.
Biosynexus' mission is bringing products to the market for the prevention and treatment of bacterial infections with emphasis on the prevention of staphylococcal infections in VLBW infants.
Company Details
- Founded
- -
- Industry
- Biotechnology
- Website
- biosynexus.com
Biosynexus Incorporated Questions
Biosynexus Incorporated's website is biosynexus.com
Biosynexus Incorporated's LinkedIn profile is https://www.linkedin.com/company/biosynexus-incorporated
Biosynexus Incorporated's industry is
Biotechnology
Biosynexus Incorporated's top competitors are
Biocryst Pharmaceuticals, Inc.,
Impulse Dynamics,
Boston Scientific,
Ambu Usa,
Crescent Biopharma,
Best Medical International,
Total Emedical, Inc.,
Glycomimetics.
Biosynexus Incorporated's categories are Biotechnology
Biosynexus Incorporated's founding year is 1999
